HEALTHQUARTZ
Abivax stock surges as new trial data ease cancer fears over bowel disease drug
Abivax stock surged following new Phase 3 trial data indicating malignancy rates among ulcerative colitis patients align with typical expectations, easing concerns about cancer risks linked to the bowel disease drug.
Mentioned
Related Signal
Adjacent reporting
- STAT+: Abivax ulcerative colitis drug shows strong efficacy, but cases of cancer raise concerns
- STAT+: Abivax seeks to ease safety concerns with new data, boosting shares
- French biotech stock soars 31% after new data on experimental medicine
- Biotech takeover target Abivax sinks over 30% after bowel disease drug trial update
- Scientists FINALLY work out what increases the risk of early-age bowel cancer - shedding a light on the mysterious rise in cases in under 50s
- STAT+: Radiopharmaceutical shows promise in post-Pluvicto setting